Recursion Pharmaceuticals FY Conference Summary Company Overview - **Company**: Recursion Pharmaceuticals (NasdaqGS:RXRX) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 13, 2026 Key Industry Insights - **Focus on AI in Drug Development**: Recursion emphasizes the integration of AI in drug discovery and development, aiming to decode complex biological processes to create effective medicines [3][4][5] - **Patient-Centric Approach**: The company prioritizes patient needs, focusing on developing better medicines faster and at scale [3][4] Core Company Highlights - **Clinical Programs**: Recursion has five clinical programs and 15 discovery programs, with a notable achievement of their first AI-enabled clinical proof of concept [5][6] - **Financial Position**: The company reported $755 million in cash at year-end 2025, providing a runway until the end of 2027. They expect a cash burn of less than $390 million in 2026, a 35% reduction from 2024 [5][10][24] - **Partnerships**: Recursion has secured over $500 million in upfront and milestone payments from partnerships with companies like Roche, Genentech, and Sanofi, with potential milestones averaging over $300 million per program [5][6] Clinical Development Insights - **REC-4881 Program**: This program targets familial adenomatous polyposis (FAP), a disease with over 50,000 patients in the US and EU and no approved pharmacotherapies. The program has shown a 75% patient response rate and significant polyp reduction [12][15][25] - **Regulatory Engagement**: The company plans to engage with the FDA in the first half of 2026 to define a registrational study plan for REC-4881, utilizing real-world evidence to support their case [27][29] Technological Advancements - **AI-Native Platform**: Recursion's platform integrates wet and dry lab capabilities, allowing for the generation of over 100 million AI-generated molecules, significantly speeding up the drug development process [20][21] - **Phenomics and Omics Data**: The company is layering omics data onto their phenomics approach to enhance target identification and drug development efficiency [19][20] Future Milestones - **Upcoming Data Releases**: Key upcoming milestones include early safety and pharmacokinetic data for the RBM39 program and further developments in their partnership programs with Roche and Sanofi [39][40][41] - **Focus on Novel Targets**: Recursion aims to continue identifying and developing first-in-class programs through their innovative AI-driven methodologies [40][41] Additional Considerations - **Market Positioning**: Recursion positions itself as a leader in AI-driven drug discovery, emphasizing the importance of high-quality data generation and the integration of technology in pharmaceutical development [31][32][36] - **Cultural and Operational Discipline**: The company highlights the importance of maintaining a motivated team and disciplined operations to drive success in their mission [46][47] This summary encapsulates the key points discussed during the conference, focusing on Recursion Pharmaceuticals' strategic direction, clinical advancements, and financial health.